Antisense Oligonucleotide Brain Delivery is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA or RNA molecules designed to modulate gene expression by binding to complementary messenger RNA (mRNA) sequences. ASO-based therapeutics represent one of the most advanced approaches for direct genetic intervention in the central nervous system (CNS), offering precise targeting of disease-causing proteins while avoiding the risks associated with viral vector delivery.
Antisense oligonucleotide (ASO) therapy represents one of the most promising approaches for treating neurodegenerative diseases by directly targeting disease-causing genes at their source. Unlike small molecule drugs that must interact with protein targets, ASOs can be designed to selectively bind to any messenger RNA (mRNA) sequence, thereby reducing production of toxic proteins or modulating splicing patterns.
The key advantages of ASO therapeutics include:
This page provides comprehensive coverage of ASO delivery methods, mechanisms of action, clinical trials, and emerging therapeutic applications for neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's, and ALS.
ASOs exert their effects through two primary mechanisms:
RNase H-Dependent Degradation: ASOs designed with a DNA-like backbone recruit RNase H, an endogenous enzyme that cleaves the RNA strand of DNA-RNA hybrids. This leads to degradation of the target mRNA and subsequent reduction in protein production[1].
Steric Block Mechanism: ASOs designed with modified backbones (e.g., morpholinos, LNAs) do not recruit RNase H but instead physically block translational initiation, splice sites, or miRNA binding sites, modulating gene expression without degrading the target mRNA[2].
The development of ASO chemistry has progressed through multiple generations, each improving stability, binding affinity, and therapeutic potential:
| Generation | Modifications | Key Features | Examples |
|---|---|---|---|
| 1st | Phosphorothioate (PS) backbone | Nuclease resistance, protein binding | Formivirsen (CMV retinitis) |
| 2nd | 2'-O-methyl, 2'-O-methoxyethyl (MOE) | Improved binding affinity, reduced toxicity | Nusinersen, Tofersen |
| 3rd | Locked Nucleic Acid (LNA), PNA, PMO | High affinity, RNase H-independent | Mipomersen, Eteplirsen |
Phosphorothioate (PS) backbone: The substitution of sulfur for non-bridging oxygen in the phosphate group provides nuclease resistance and enables RNase H recruitment[3].
2'-O-methoxyethyl (MOE): This modification at the 2' position of the ribose sugar significantly increases binding affinity to target RNA while reducing off-target effects and improving pharmacokinetics[4].
Locked Nucleic Acid (LNA): LNAs contain a methylene bridge connecting the 2'-O and 4'-C atoms, locking the ribose in the C3'-endo conformation. This dramatically increases thermal stability and allows for shorter ASO sequences[5].
Two ASO therapeutics have received FDA approval for CNS indications:
Approved in 2016 for spinal muscular atrophy (SMA), nusinersen targets the SMN2 gene to increase production of functional survival motor neuron (SMN) protein[6].
Approved in 1-associated amyotrophic lateral sclerosis (ALS), tofersen represents the first gene-silencing therapy for ALS[7].
Multiple ASO candidates are in clinical development for neurodegenerative diseases:
| Drug | Target | Indication | Phase | Company |
|---|---|---|---|---|
| Tominersen (RG6042) | HTT | Huntington's disease | Phase 2/3 (discontinued) | Roche/Ionis |
| BIIB080 (IONIS-MAPT) | MAPT | Alzheimer's disease | Phase 1/2 | Biogen/Ionis |
| ION363 (Jacifusen) | FUS | FUS-ALS | Phase 1/2 | Ionis/Academia |
| WVE-004 | C9orf72 | ALS/FTD | Phase 1/2 | Wave Life Sciences |
| BIIB078 | C9orf72 | ALS | Phase 1 | Biogen/Ionis |
| RO7065031 | SNCA | Parkinson's disease | Phase 1 | Roche |
The huntingtin (HTT) gene ASO was evaluated in the GENERATION HD1 trial for early-stage Huntington's disease. Despite reducing mutant huntingtin protein by 40%, the trial was discontinued in 2021 due to lack of clinical benefit compared to placebo[8]. This outcome highlighted the challenges of treating neurodegeneration after symptom onset.
Targeting microtubule-associated protein tau (MAPT), this ASO aims to reduce tau protein production in Alzheimer's disease. Phase 1/2 results showed dose-dependent reduction in total tau and phospho-tau in CSF[9].
Fused in sarcoma (FUS) mutations cause a aggressive form of ALS. ION363 has shown promise in reducing FUS protein in preclinical models and is now in clinical testing for FUS-ALS patients[10].
Understanding ASO distribution is critical for CNS delivery:
ASOs enter neurons and glia through multiple mechanisms:
Once inside cells, ASOs accumulate in endosomes and gradually release into the cytoplasm and nucleus where they engage their targets[11].
Chemical conjugation can enhance tissue-specific delivery:
Systemic administration faces the challenge of crossing the blood-brain barrier (BBB). Newer chemistries aim to enable peripheral administration with CNS penetration:
| Method | Advantages | Challenges |
|---|---|---|
| Intrathecal | Direct CSF access, established | Invasive, distribution limited |
| Intracerebroventricular | Broader CNS distribution | Requires surgery |
| Convection-Enhanced Delivery | Bulk flow distribution | Requires implants |
ASOs can hybridize to unintended transcripts, particularly when there is partial sequence complementarity. Mitigation strategies include:
PS-modified ASOs can activate innate immune responses through toll-like receptor (TLR) binding. Strategies to reduce immunogenicity include:
White blood cell pleocytosis and elevated protein are commonly observed after intrathecal ASO administration but are generally transient and not clinically significant[13].
| Modality | Mechanism | Delivery | Clinical Stage |
|---|---|---|---|
| ASO | RNase H or steric block | Intrathecal | FDA-approved |
| siRNA | RNA-induced silencing | Liver (GalNAc) | FDA-approved |
| miRNA mimics/inhibitors | Modulate miRNA activity | Various | Clinical trials |
| Splice-switching | Pre-mRNA splicing modulation | Intrathecal | FDA-approved |
The study of Antisense Oligonucleotide Brain Delivery has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Rigo F, Seth PP, Bennett CF. Antisense oligonucleotide-based therapies for diseases of the nervous system. Nat Drug Discov. 2020;19(9):671-688. ↩︎
Karkare S, Bhatnagar D. Promising RNA interference (RNAi)-based therapies for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2021;21(4):489-501. ↩︎
Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24(6):374-387. ↩︎
Bennett CF, Baker BF, Pham N, et al. Pharmacology of 2'-O-methoxyethyl containing antisense oligonucleotides. Nucleic Acids Res. 2017;45(9):5613-5625. ↩︎
Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers. 2010;7(3):536-542. ↩︎
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732. ↩︎
Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of tofersen for SOD1 ALS. N Engl J Med. 2020;383(11):1096-1107. ↩︎
Tabrizi SJ, Leavitt BR, Landles C, et al. Targeting huntingtin expression in patients with Huntington's disease. N Engl J Med. 2019;381(5):488-489. ↩︎
Mummadi S, et al. BIIB080 (IONIS-MAPT): results from a phase 1/2 study. Presented at CTAD 2022. ↩︎
Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in FUS-ALS. Nat Med. 2022;28(1):104-116. ↩︎
Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46-51. ↩︎
Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44(14):6518-6548. ↩︎
Haché M, Swoboda KJ, Sethna N, et al. Intrathecal injections in children with spinal muscular atrophy: single-center experience. J Neuromuscul Dis. 2021;8(2):273-282. ↩︎